• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

18FFLT - A new stem cell label for in vivo tracking with positron emission tomography
Conclusions In conclusion, [18F]FLT labeling of sheep MSCs is feasible. 60min incubation time with the tracer does not perturb the biologic and functional properties of adult sheep MSCs in vitro. This labeling method and optimization strategy has led to pilot studies investigating the biodistribution of [18F]FLT-labeled MSCs in mice using small-animal PET/MRI. Future studies will also determine whether [18F]FLT-labeled MSCs can be tracked over time in a large animal model to assess the therapeutic potential of MSCs after stroke.
Source: Journal of Nuclear Medicine - May 23, 2016 Category: Nuclear Medicine Authors: GroAYmann, U., Zeisig, V., McLeod, D., Dreyer, A., Patt, M., Schildan, A., Sabri, O., Boltze, J., Barthel, H. Tags: SPECIAL MTA: Preclinical Probes for Neuroimaging Posters Source Type: research

Spatiotemporal PET Imaging of Dynamic Metabolic Changes After Therapeutic Approaches of Induced Pluripotent Stem Cells, Neuronal Stem Cells, and a Chinese Patent Medicine in Stroke
Conclusion: Spatiotemporal PET imaging with 18F-FDG demonstrated dynamic metabolic and functional recovery after iPSCs or NSCs combined with QKL in a rat model of cerebral ischemia–reperfusion injury. iPSCs or NSCs combined with Chinese medicine QKL seemed to be a better therapeutic approach than these stem cells used individually.
Source: Journal of Nuclear Medicine - November 2, 2015 Category: Nuclear Medicine Authors: Zhang, H., Song, F., Xu, C., Liu, H., Wang, Z., Li, J., Wu, S., YehuaShen, , Chen, Y., Zhu, Y., Du, R., Tian, M. Tags: Basic Science Investigations Source Type: research

64Cu PET Imaging of the CXCR4 Chemokine Receptor Using a Cross-Bridged Cyclam Bis-Tetraazamacrocyclic Antagonist
Conclusion: The tetraazamacrocyclic small molecule 64Cu-CuCB-bicyclam has been shown to be an imaging agent for the CXCR4 receptor that is likely to be applicable across a range of species. It has high affinity and stability and is suitable for preclinical research in immunocompetent murine models.
Source: Journal of Nuclear Medicine - January 1, 2020 Category: Nuclear Medicine Authors: Burke, B. P., Miranda, C. S., Lee, R. E., Renard, I., Nigam, S., Clemente, G. S., DHuys, T., Ruest, T., Domarkas, J., Thompson, J. A., Hubin, T. J., Schols, D., Cawthorne, C. J., Archibald, S. J. Tags: Basic Source Type: research